Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

06 October 2020 : Case report  China (mainland)

Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review

Unusual clinical course

Yanhua Yue1ABCDEFG, Wei Wei1ABCDEF, Yanting Guo1B, Fei Wang1C, Weimin Dong1D, Yue Liu1B, Yan Lin1G, Yang Cao1G, Weiying Gu1ABCDEFG*

DOI: 10.12659/AJCR.925151

Am J Case Rep 2020; 21:e925151

Table 1. Characteristics of patients with MF and CML with coexisting JAK2 gene mutations and BCR-ABL1 translocations since 2005.

Age (years)SexDiagnosis (+CML)TreatmentCoursePhaseClone interactionReference number
50MMFHU then ICML, MF 4 years laterCPBCR-ABL disappeared, JAK2 constant[]2
66MMFI then HUConcomitantCP??[]3
55MMFICML, MF 2 years laterAPBCR-ABL decreased, JAK2 increased[]4
49MMFI then DCML, MF 2 years laterCPBCR-ABL and JAK2 decreased[]5
64MMFI then NConcomitantAPBCR-ABL decreased, JAK2 constant[]5
52FMFHU then IConcomitantCPBCR-ABL and JAK2 decreased[]6
58MMFI then HUMF, CML 4 years later?BCR-ABL decreased, JAK2 increased[]7
67MMFI then HUConcomitantCP?[]8
58FMFHU, INFConcomitantCP??[]9
67MMFN then DMF, CML 3 years laterCPBCR-ABL decreased, JAK2 constant[]10
58MMFHU, DConcomitant??[]11
75MMFI then HUConcomitantCP??[]12
54FMFI\N\DConcomitantCPBCR-ABL decreased, JAK2 constant[]13
56MPV/MFHU then RPV/MF, CML? 16.1 years later[]14
73FET/MFHU then RET/MF, CML? 9.6 years laterBCR-ABL and JAK2 decreased[]14
44FPV/MFINF, R then IPV/MF, CML 5.0 years later[]14
40FET/MFR, I then BET/MF, CML 33 years laterCP[]14
76FET/MFA, I, P, R, Ara-cET/MF, CML 10 years laterCP-AP-BP[]14
48FMFN, HU, RPMF, CML 10.75 years laterCPBCR-ABL and JAK2 decreased[]15
66FET/MFHU, R, I, BET/MF, CML 3.75 years laterCP[]15
48FPV/MFPhleb, HU, INF, I, RPV/MF, CML 4.83 years laterCP[]15
60FPV/MFHU, Th, R, IPV/MF, CML 8.9 years later[]15
70MMFI, N, D, HUConcomitantBCR-ABL increased, JAK2 decreased[]15
50FMFIA/DConcomitantBPBCR-ABL and JAK2 decreasedOur case
A – anagrelide; AP – accelerated phase; Ara-c – cytarabine; B – bosutinib; BP – blast phase; CML – chronic myelogenous leukemia; CP – chronic phase; D – dasatinib; ET/MF – myelofibrosis secondary to essential thrombocytosis; F – Female; HU – hydroxyurea; I – imatinib; INF – interferon; IA – idarubicin and cytarabine; M – Male; MF – myelofibrosis; N – nilotinib; PV/MF – myelofibrosis secondary to polycythemia vera; P – ponatinib; Phleb – therapeutic phlebotomy; R – ruxolitinib; Th – thalidomide.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923